NOTICE IS HEREBY GIVEN that the Annual General Meeting (the "AGM" or the "Meeting") of NANOFILM TECHNOLOGIES INTERNATIONAL LIMITED (the "Company") will be held by way of electronic means on Friday, 28 April 2023 at 10.00 a.m. (Singapore time) to transact the following business:

#### **AS ORDINARY BUSINESS**

1. To receive and adopt the Directors' Statement and Audited Financial Statements of the Company for the year ended 31 December 2022 together with the Auditors' Report thereon.

**Resolution 1** 

2. To declare a final dividend (tax exempt one-tier) of S\$0.011 per ordinary share for the financial year ended 31 December 2022.

Resolution 2

3. To re-elect the following Directors of the Company who will each retire pursuant to the relevant Regulations of the Company's Constitution, and who each being eligible, offers himself for re-election:

Dr Shi Xu	(Regulation 94)	Resolution 3
Mr Kristian John Robinson	(Regulation 94)	Resolution 4
Mr Wan Kum Tho	(Regulation 94)	Resolution 5
Mr Steve Ghanayem	(Regulation 100)	Resolution 6

Dr Shi Xu will, upon re-election as a Director of the Company, remain as the Executive Chairman of the Board. Detailed information of Dr Shi Xu required pursuant to Rule 720(6) of the Listing Manual of the Singapore Exchange Securities Trading Limited ("SGX-ST") can be found in the Annual Report.

Mr Kristian John Robinson will, upon re-election as a Director of the Company, remain as the Chairman of the Nominating Committee and a member of the Remuneration Committee, and will be considered independent. Detailed information of Mr Kristian John Robinson required pursuant to Rule 720(6) of the Listing Manual of SGX-ST can be found in the Annual Report.

Mr Wan Kum Tho will, upon re-election as a Director of the Company, remain as the Chairman of the Board Risk Committee and a member of the Audit Committee, and will be considered independent. Detailed information of Mr Wan Kum Tho required pursuant to Rule 720(6) of the Listing Manual of SGX-ST can be found in the Annual Report.

Mr Steve Ghanayem will, upon re-election as a Director of the Company, remain as a member of the Board Risk Committee and will be considered independent. Detailed information of Mr Steve Ghanayem required pursuant to Rule 720(6) of the Listing Manual of SGX-ST can be found in the Annual Report.

To approve the payment of additional Directors' fees of S\$10,027.40 for the financial year ended 31 December 2022 ("FY2022").

[See Explanatory Note (i)] Resolution 7

5. To approve the payment of Directors' fees of S\$588,000.00 for the financial year ending 31 December 2023, to be paid quarterly in arrears.

**Resolution 8** 

6. To re-appoint Moore Stephens LLP as the Auditors of the Company and to authorise the Directors to fix their remuneration.

Resolution 9

7. To transact any other ordinary business which may be transacted at an AGM.

### **AS SPECIAL BUSINESS**

To consider, and if thought fit, pass with or without any amendments, the following Ordinary Resolutions:

### 8. SHARE ISSUE MANDATE

That pursuant to Section 161 of the Companies Act 1967 of Singapore ("Companies Act"), and Rule 806 of the Listing Manual of the SGX-ST, authority be and is hereby given to the Directors to:

- (a) (i) allot and issue ordinary shares in the capital of the Company ("**Shares**") whether by way of rights, bonus or otherwise;
  - (ii) make or grant offers, agreements or options (collectively, "Instruments") that might or would require Shares to be issued, including but not limited to the creation and issue of (as well as adjustments to) options, warrants, debentures or other similar instruments convertible into Shares; and/or
  - (iii) issue additional Instruments arising from adjustments made to the number of Instruments previously issued in the event of rights, bonus or capitalisation issues,

at any time and upon such terms and conditions and for such purposes and to such persons as the Directors may in their absolute discretion deem fit;

- (b) (notwithstanding the authority conferred by this Resolution may have ceased to be in force) issue Shares in pursuance of any Instrument made or granted by the Directors while this Resolution was in force; and
- (c) complete and do all such acts and things, including without limitation, executing all such documents and approving any amendments, alterations or modifications to any documents as they may consider necessary, desirable or expedient to give effect to this Resolution.

#### provided that:

- (1) the aggregate number of Shares to be issued pursuant to this Resolution (including Shares to be issued in pursuance of the Instruments made or granted pursuant to this Resolution) shall not exceed 50% of the total number of issued Shares (excluding treasury shares and subsidiary holdings, if any)(as calculated in accordance with sub-paragraph (2) below), of which the aggregate number of Shares to be issued other than on a *pro-rata* basis to shareholders of the Company ("**Shareholders**") (including Shares to be issued in pursuance of the Instruments made or granted pursuant to this Resolution) shall not exceed 20% of the total number of issued Shares (excluding treasury shares and subsidiary holdings, if any) (as calculated in accordance with sub-paragraph (2) below):
- (2) (subject to such manner of calculation as may be prescribed by the SGX-ST) for the purpose of determining the aggregate number of Shares that may be issued under sub-paragraph (1) above, the total number of the issued Shares (excluding treasury shares and subsidiary holdings, if any) shall be based on the total number of issued Shares (excluding treasury shares and subsidiary holdings, if any) at the time of the passing of this Resolution, after adjusting for:
  - (a) new Shares arising from the conversion or exercise of any convertible securities;
  - (b) new Shares arising from the exercise of share options or vesting of share awards, provided the options or awards were granted in compliance with Part VIII of Chapter 8 of the Listing Manual of the SGX-ST; and
  - (c) any subsequent bonus issue, consolidation or subdivision of shares;
- (3) in exercising the authority conferred by this Resolution, the Company shall comply with the provisions of the Listing Manual of the SGX-ST for the time being in force (unless such compliance has been waived by the SGX-ST) and the Constitution for the time being of the Company; and
- (4) (unless revoked or varied by the Company in a general meeting), the authority conferred by this Resolution shall continue in force until the conclusion of the next AGM of the Company or the date by which the next AGM of the Company is required by law to be held, whichever is the earlier.

Adjustments in accordance with sub-paragraph (2)(a) or sub-paragraph (2)(b) above are only to be made in respect of new Shares arising from convertible securities, share options or share awards which were issued and outstanding or subsisting at the time of the passing of this Resolution.

[See Explanatory Note (ii)] Resolution 10

### 9. AUTHORITY TO ISSUE SHARES UNDER THE NANOFILM EMPLOYEE SHARE OPTION SCHEME 2017 ("ESOS 2017")

That pursuant to Section 161 of the Companies Act, authority be and is hereby given to the Directors to allot and issue new fully-paid Shares ("**New Shares**") from time to time as may be required to be issued pursuant to the exercise of the options granted under the ESOS 2017 and that such authority shall, unless revoked or varied by the Company in a general meeting, continue in force until the conclusion of the next AGM of the Company or the date by which the next AGM of the Company is required by law to be held, whichever is earlier.

[See Explanatory Note (iii)] Resolution 11

### 10. AUTHORITY TO GRANT OPTIONS AND ISSUE SHARES UNDER THE NANOFILM EMPLOYEE SHARE OPTION SCHEME 2020 (THE "NANOFILM ESOS 2020")

That pursuant to Section 161 of the Companies Act, authority be and is hereby given to the Directors to:

- (a) offer and grant options pursuant to the rules of the Nanofilm ESOS 2020 and that such authority shall, unless revoked or varied by the Company in a general meeting, continue in force until the conclusion of the next AGM of the Company or the date by which the next AGM of the Company is required by law to be held, whichever is earlier ("Relevant Period"); and
- (b) allot and issue New Shares as may be required to be issued from time to time pursuant to the exercise of options granted during the Relevant Period,

provided that the total number of Shares over which options may be granted under the Nanofilm ESOS 2020 on any date, when added to the total number of New Shares allotted and issued and/or to be allotted and issued, and issued Shares (including treasury shares and subsidiary holdings, if any) delivered and/or to be delivered, pursuant to (i) options already granted under the Nanofilm ESOS 2020; (ii) awards already granted the Nanofilm Restricted Share Plan (as defined in paragraph 11 below); and (iii) any options and awards already granted under the Company's other share options or share schemes adopted post the initial public offering of the Shares on the SGX-ST ("Listing"), shall not exceed 5% of the total number of issued Shares (excluding treasury shares and subsidiary holdings, if any) on the date preceding the date of grant of the relevant new option.

[See Explanatory Note (iv)] Resolution 12

### 11. AUTHORITY TO GRANT AWARDS AND ISSUE SHARES UNDER THE NANOFILM RESTRICTED SHARE PLAN (THE "NANOFILM RESTRICTED SHARE PLAN")

That pursuant to Section 161 of the Companies Act, authority be and is hereby given to the Directors to:

- (a) offer and grant awards ("Awards") in accordance with the provisions of the Nanofilm Restricted Share Plan and that such authority shall, unless revoked or varied by the Company in a general meeting, continue in force during the Relevant Period: and
- (b) allot and issue New Shares, as may be required to be issued from time to time pursuant to the vesting of Awards under the Nanofilm Restricted Share Plan,

provided that the total number of Shares which may be delivered pursuant to Awards granted under the Nanofilm Restricted Share Plan, when added to: (i) the total number of New Shares allotted and issued and/or to be allotted and issued, issued Shares (including treasury shares and subsidiary holdings, if any) delivered and/or to be delivered, and Shares released and/or to be released in the form of cash in lieu of Shares, pursuant to all Awards granted under the Nanofilm Restricted Share Plan; (ii) the total number of new Shares allotted and issued and/or to be allotted and issued, and issued Shares (including treasury shares and subsidiary holdings, if any) delivered and/or to be delivered, pursuant to options already granted under the Nanofilm ESOS 2020; and (iii) the total number of Shares subject to any other share option or share schemes adopted by the Company after the Listing, shall not exceed 5% of the total number of issued Shares (excluding Shares held by the Company as treasury shares and subsidiary holdings, if any) from time to time.

[See Explanatory Note (v)] Resolution 13

#### 12. RENEWAL OF SHARE PURCHASE MANDATE

That:

- (a) for the purposes of Section 76C and 76E of the Companies Act, the exercise by the Directors of all the powers of the Company to purchase or otherwise acquire Shares not exceeding in aggregate the Maximum Limit (as hereafter defined), at such price or prices as may be determined by the Directors from time to time up to the Maximum Price (as hereafter defined), whether by way of:
  - (i) on-market purchase(s) ("Market Purchases"), transacted through the SGX-ST trading system and/or on any other securities exchange on which the Shares may for the time being be listed and quoted, through one or more duly licensed dealers appointed by the Company for the purpose; and/or
  - (ii) off-market purchase(s) ("**Off-Market Purchase**"), if effected otherwise than on the SGX-ST or a securities exchange in accordance with an equal access scheme(s)(as defined in Section 76C of the Companies Act) as may be determined or formulated by the Directors as they consider fit, which scheme(s) shall satisfy all the conditions prescribed by the Companies Act,

and otherwise in accordance with the Companies Act and all other laws and regulations and rules of the SGX-ST as may for the time being be applicable, be and is hereby authorised and approved generally and unconditionally (the "Share Purchase Mandate");

- (b) unless varied or revoked by the Company in general meeting, the authority conferred on the Directors pursuant to the Share Purchase Mandate may be exercised by the Directors at any time and from time to time during the period commencing on and from the date of the passing of this Resolution and expiring on the earlier of:
  - (i) the date on which the next AGM of the Company is held or required by law to be held; or
  - (ii) the date on which purchases and acquisitions of Shares pursuant to the Share Purchase Mandate are carried out to the full extent mandated.
- (c) for purposes of this Resolution:-

"Average Closing Price" means the average of the closing market prices of the Shares over the last five (5) consecutive market days on which Shares are transacted on the SGX-ST or, as the case may be, such other securities exchange on which the Shares may for the time being be listed or quoted, immediately preceding the date of the Market Purchase by the Company or, as the case may be, the date of the making of the offer pursuant to the Off-Market Purchase, and deemed to be adjusted in accordance with the Listing Manual of the SGX-ST for any corporate action which occurs during the relevant five-day (5) market days period and the date on which the Market Purchase is made or, as the case may be, the date of the making of the offer pursuant to the Off-Market Purchase;

"date of the making of the offer" means the day on which the Company announces its intention to make an offer for an Off-Market Purchase or acquisition of Shares from Shareholders, stating the purchase price (which shall not be more than the Maximum Price for an Off-Market Purchase calculated on the basis set out below) for each Share and the relevant terms of the equal access scheme for effecting the Off-Market Purchase;

"Maximum Limit" means that number of issued Shares representing 10% of the total issued Shares as at the date of the passing of this Resolution (excluding any Shares which are held as treasury shares and subsidiary holdings as at that date); and

"Maximum Price" in relation to a Share to be purchased or acquired, means the purchase price (excluding related brokerage, commission, applicable goods and services tax, stamp duties, clearance fees and other related expenses) which shall not exceed, in the case of a Market Purchase, 105% of the Average Closing Price of the Shares and, in the case of an Off-Market Purchase pursuant to an equal access scheme, 120% of the Average Closing Price of the Shares; and

(d) the Directors and/or any of them be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) as they and/or he may consider expedient or necessary to give effect to the transactions contemplated and/or authorised by this Resolution.

[See Explanatory Note (vi)] Resolution 14

By Order of the Board

Eunice Hooi Company Secretary

Singapore 13 April 2023

#### Explanatory Notes on Resolutions to be passed

- (i) The additional Directors' fees are due to the addition of one new Board member during FY2022.
- (ii) Ordinary Resolution 10 proposed in item 8 above, if passed, will empower the Directors, until the conclusion of the next AGM of the Company, or the date by which the next AGM of the Company is required by law to be held, or such authority is revoked or varied by the Company in a general meeting, whichever is the earlier, to issue Shares, make or grant Instruments convertible into Shares and to issue Shares pursuant to such Instruments, up to a number not exceeding, in total, 50% of the total number of issued Shares (excluding treasury shares and subsidiary holdings, if any), of which up to 20% may be issued other than on a pro-rata basis to Shareholders.
  - For the purpose of determining the aggregate number of Shares that may be issued, the total number of issued Shares (excluding treasury shares and subsidiary holdings, if any) will be calculated based on the total number of issued Shares (excluding treasury shares and subsidiary holdings, if any) at the time Ordinary Resolution 10 is passed, after adjusting for new Shares arising from the conversion or exercise of any convertible securities or share options or vesting of share awards which were issued and outstanding or subsisting at the time when this Resolution is passed, and any subsequent bonus issue, consolidation or subdivision of Shares.
- (iii) Ordinary Resolution 11 proposed in item 9 above, if passed, will empower the Directors of the Company to issue from time to time such number of Shares as may be required to be issued pursuant to the exercise of options already granted under the ESOS 2017.
- (iv) Ordinary Resolution 12 proposed in item 10 above, if passed, will empower the Directors of the Company to offer and grant options pursuant to the rules of the Nanofilm ESOS 2020 from the date of the passing of Ordinary Resolution 12 until the conclusion of the next AGM of the Company, or the date by which the next AGM of the Company is required by law to be held, whichever is the earlier and to allot and issue from time to time such number of Shares as may be required to be issued pursuant to the exercise of options granted or to be granted under the Nanofilm ESOS 2020. The aggregate number of shares which may be issued pursuant to the Nanofilm ESOS 2020, the Nanofilm Restricted Share Plan and any other share option or share schemes adopted by the Company post-Listing shall not exceed 5% of the total number of issued Shares (excluding treasury shares and subsidiary holdings, if any) on the date preceding the date of grant of the relevant new option.
- Ordinary Resolution 13 proposed in item 11 above, if passed, will empower the Directors of the Company to offer and grant Awards in accordance with the provisions of the Nanofilm Restricted Share Plan from the date of the passing of Ordinary Resolution 13 until the conclusion of the next AGM of the Company, or the date by which the next AGM of the Company is required by law to be held, whichever is the earlier, and to allot and issue from time to time such number of fully-paid New Shares as may be required to be issued pursuant to the vesting of Awards under the Nanofilm Restricted Share Plan. The aggregate number of shares which may be delivered pursuant to Awards granted under the Nanofilm Restricted Share Plan on any date, when added to [1] the total number of new Shares allotted and issued, issued Shares (including treasury shares and subsidiary holdings, if any) delivered and/or to be released in the form of cash in lieu of Shares, pursuant to all Awards granted under the Nanofilm Restricted Share Plan, [2] the total number of new Shares allotted and issued and/or to be allotted and issued, and issued Shares (including treasury shares and subsidiary holdings, if any) delivered and/or to be delivered, pursuant to options granted under the Nanofilm ESOS 2020 and (3) the total number of Shares subject to any other share option or share schemes adopted by the Company post-Listing, shall not exceed 5% of the total number of issued Shares (excluding Shares held by the Company as treasury shares and subsidiary holdings, if any) on the date preceding the date of the relevant Award.

Ordinary Resolution 14 proposed in item 12 above, is to renew the mandate approved by Shareholders at the last AGM held on 28 April 2022 to enable the Directors to purchase or otherwise acquire Shares on the terms and subject to the conditions of this Resolution. If passed, Ordinary Resolution 14 will empower the Directors until the conclusion of the next AGM of the Company, or the date by which the next AGM of the Company is required by law to be held, whichever is the earlier, to repurchase Shares by way of Market Purchases or Off-Market Purchases of up to 10% of the total number of issued Shares (excluding treasury shares and subsidiary holdings, if any) as at the date of the AGM at which the Resolution is passed. The rationale for, the authority and limitation on, the sources of funds to be used for the purchase or acquisition including the amount of financing and the financial effects of the purchase or acquisition of Shares by the Company pursuant to the proposed renewal of the Share Purchase Mandate on the audited consolidated financial statements of the Company and its subsidiaries for the financial year ended 31 December 2022 are set out in greater detail in the Addendum released on the SGX website together with the Annual Report 2022 ("Addendum").

#### PARTICIPATION IN THE ANNUAL GENERAL MEETING ("AGM")

The AGM will be held by electronic means pursuant to the COVID-19 (Temporary Measures) (Alternative Arrangements for Meetings for Companies, Variable Capital Companies, Business Trusts, Unit Trusts and Debenture Holders) Order 2020, and Shareholders will NOT be able to attend the AGM in person.

Printed copies of all documents relating to the business of AGM, including the Annual Report 2022, the Addendum, this Notice of AGM and Proxy Form will not be sent to Shareholders of the Company. Instead, the Annual Report 2022, the Addendum, this Notice of AGM and Proxy Form will be published on the SGX website at the URL <a href="https://www.sgx.com/securities/company-announcements">https://www.sgx.com/securities/company-announcements</a> and the Company's website at the URL <a href="https://www.nti-nanofilm.com/investors/announcements">https://www.nti-nanofilm.com/investors/announcements</a>.

All Shareholders or their corporate representatives (in the case of Shareholders which are legal entities) will be able to participate in the AGM proceedings by watching a "live" webcast (the "Live AGM Webcast") or listen to a "live" audio feed (the "Live AGM Audio Feed").

#### PRE-REGISTRATION

- To attend the AGM through the Live AGM Webcast or Live AGM Audio Feed, Shareholders or their corporate representatives (in the case of members of the Company ("Members") which are legal entities) will need to register at <a href="https://septusasia.com/nanofilm2023agm">https://septusasia.com/nanofilm2023agm</a> by 10:00 a.m. on 25 April 2023 (the "Registration Deadline") for verification of their status as Shareholders (or the corporate representatives of such Shareholders) of the Company. Shareholders who wish to appoint person(s) (other than the Chairman of the Meeting) as a proxy(ies) ("Proxyholder(s)") to attend and vote at the AGM must register their appointed proxy(ies) by the Registration Deadline, failing which the appointment shall be invalid.
- (iii) Shareholders/Investors holding shares through relevant intermediaries (other than CPF/SRS investors) will not be able to pre-register for the Live AGM Webcast. Such Shareholders/investors who wish to participate in the AGM proceedings should instead approach his/her relevant intermediary as soon as possible in order to make the necessary arrangements.
- [iii] Following successful verification, each such Shareholder or its corporate representative(s) or Proxy(ies) ("Attendees") will receive an email confirmation ("Confirmation Email") by 10.00 a.m. on 27 April 2023 containing instructions on how to access the live AGM proceedings through the Live AGM Webcast or Live AGM Audio Feed. Attendees must not forward the Confirmation Email to any other persons who are not Shareholders and who are not eligible to attend the AGM. This is also to avoid any potential technical disruptions to the Live AGM Webcast or Live AGM Audio Feed due to overloading.
- (iv) Attendees who have registered by the Registration Deadline but do not receive an email confirmation by 10.00 a.m. on 27 April 2023 may contact Septus Singapore Pte Ltd at +65 6641 7315 or email webcast@septusasia.com for assistance.

### APPOINTMENT OF PROXY(IES)

- (i) Shareholders (whether individual or corporate) who wish to vote on the resolutions to be tabled at the AGM may:
  - (a) vote "live" via electronic means at the AGM, or (whether the Shareholder is an individual or a corporate) appoint a proxy(ies) (other than the Chairman of the Meeting) to vote "live" via electronic means at the AGM on his/her/its behalf; or
  - (b) (whether the Shareholder is an individual or a corporate) appoint the Chairman of the Meeting as his/her/its proxy to vote on his/her/its behalf at the AGM. In appointing the Chairman of the AGM as proxy, Shareholders must give specific instructions as to voting, or abstention from voting, in respect of a resolution in the Proxy Form, failing which the appointment of the Chairman of the AGM as proxy for that resolution will be treated as invalid.
- (ii) A Shareholder who is not a relevant intermediary is entitled to appoint not more than two proxies. Where such Shareholder's proxy form appoints more than one proxy, the proportion of the shareholding concerned to be represented by each proxy shall be specified in the instrument.
- iii) A Shareholder who is a relevant intermediary is entitled to appoint more than two proxies but each proxy must be appointed to exercise the rights attached to a different share or shares held by such Shareholder. Where such Shareholder's proxy form appoints more than one proxy, the number and class of shares in relation to which each proxy has been appointed shall be specified in the instrument.

### "Relevant intermediary" means:

(a) a banking corporation licensed under the Banking Act 1970 or a wholly-owned subsidiary of such a banking corporation, whose business includes the provision of nominee services and who holds shares in that capacity;

- (b) a person holding a capital markets services licence to provide custodial services for securities under the Securities and Futures Act 2001, and who holds shares in that capacity; or
- (c) the Central Provident Fund Board ("CPF Board") established by the Central Provident Fund Act 1953, in respect of shares purchased under the subsidiary legislation made under that Act providing for the making of investments from the contributions and interest standing to the credit of members of the Central Provident Fund, if the CPF Board holds those shares in the capacity of an intermediary pursuant to or in accordance with that subsidiary legislation.
- (iv) A proxy need not be a Shareholder.
- (v) The duly executed instrument appointing the proxy[ies] (the "Proxy Form") must be deposited with the Company's Share Registrar Office at Boardroom Corporate & Advisory Services Pte. Ltd. at 1 Harbourfront Avenue Keppel Bay Tower #14-07 Singapore 098632 or emailed to AGM. TeamE@boardroomlimited. com by 10:00 a.m. on 25 April 2023, being 72 hours before the commencement of the AGM.

Shareholders are strongly encouraged to submit completed proxy forms electronically via email.

(vi) CPF or SRS investors may: (a) vote "live" via electronic means at the AGM if they are appointed as proxies by their respective CPF Agent Banks or SRS Operators, and should approach their respective CPF Agent Banks or SRS Operators if they have any queries regarding their appointment as proxies; or (b) appoint the Chairman of the Meeting as proxy to vote on their behalf at the AGM, in which case they should approach their respective CPF Agent Banks or SRS Operators to submit their votes at least seven (7) working days before the AGM (i.e.: by 19 April 2023) in order to allow sufficient time for their respective relevant intermediaries to in turn submit a Proxy Form on their behalf by the cut-off date.

#### SUBMISSION OF QUESTIONS

- (i) Shareholders or Proxy(ies) may (i) submit questions related to the resolutions to be tabled at the AGM during pre-registration by post to the Company's Share Registrar Office at Boardroom Corporate & Advisory Services Pte. Ltd. at 1 Harbourfront Avenue, #14-07 Keppel Bay Tower, Singapore 098632 or by email to AGM.TeamE@boardroomlimited.com by 10:00 a.m. on 25 April 2023; or (ii) submit text-based question during the AGM by clicking the "Ask Questions" feature and then inputting their queries in the questions text box.
- (ii) The Company will endeavour to address all substantial and relevant questions received from Shareholders either before or during the AGM.
- (iii) Minutes of the AGM will be posted on SGXNet and the Company's corporate website within one month from the date of the AGM.

#### VOTING

- (i) Live voting will be conducted during the AGM. It is important for Attendees to ensure their own web-browser enabled devices are ready for voting during the AGM.
- (ii) Attendees will be required to log-in via the username and password provided in the Confirmation Email.
  - (a) Live voting: Attendees may cast their votes in real time for each resolution to be tabled via the Live AGM Webcast. Attendees will have the opportunity to cast their votes via the live voting feature.
  - (b) Voting via appointing the Chairman of the Meeting as Proxy: As an alternative to the above, Members may also appoint the Chairman of the AGM as his/her/its proxy to vote on their behalf. Please refer to "Appointment of proxy(ies)" section above for the manner of submission.

#### PERSONAL DATA PRIVACY:

By (a) submitting an instrument appointing the proxy(ies) to vote at the AGM and/or any adjournment thereof, or (b) completing the pre-registration in accordance with this Notice, or (c) submitting any question prior to the AGM in accordance with this Notice, a Member consents to the collection, use and disclosure of the Member's personal data by the Company (or its agents or service providers) for the following purposes:

- (i) the processing and administration by the Company (or its agents or service providers) of Proxy Forms appointing proxy(ies) for the AGM (including any adjournment thereof);
- the processing of the pre-registration for purposes of granting access to Members (or their corporate representatives in the case of Members which are legal entities) to observe the AGM proceedings and providing them with any technical assistance where necessary;
- (iii) addressing relevant and substantial questions from Members and if necessary, following up with the relevant Members in relation to such questions;
- (iv) the preparation and compilation of the attendance lists, proxy lists, minutes and other documents relating to the AGM (including any adjournment thereof); and
- (v) enabling the Company (or its agents or service providers) to comply with any applicable laws, listing rules, regulations and/or guidelines